Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Vermersch

Showing results (171-180 of 250) with videos related to

Pageof 25
Sort By:
Autoimmunity Reviews|January 19, 2018
Altered B lymphocyte homeostasis and functions in systemic sclerosisAlexandra Forestier, Thomas Guerrier, Mathieu Jouvray, et al.
Multiple Sclerosis and Related Disorders|February 12, 2021
Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS studyBruce A C Cree, James D Bowen, Hans-Peter Hartung, et al.
Digital Health|May 19, 2023
Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosisGavin Giovannoni, Enrique Alvarez, Ellen Tutton, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 13, 2023
Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosisJohn Kramer, Ralf Linker, David Paling, et al.
The New England Journal of Medicine|April 9, 2025
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple SclerosisRobert J Fox, Amit Bar-Or, Anthony Traboulsee, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 14, 2022
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MSNicola de Stefano, Frederik Barkhof, Xavier Montalban, et al.
Lancet (London, England)|March 27, 2018
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 studyLudwig Kappos, Amit Bar-Or, Bruce A C Cree, et al.
BMC Neurology|October 7, 2020
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosisGiancarlo Comi, Mark S Freedman, José E Meca-Lallana, et al.
Frontiers in Immunology|November 3, 2022
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year inMaura Pugliatti, Hans-Peter Hartung, Celia Oreja-Guevara, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 14, 2025
Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?Sandra Vukusic, Florian Hubben, Antoine Gavoille, et al.
Pageof 25

Showing results (171-180 of 250) with videos related to

Sort By:
Pageof 25
Autoimmunity Reviews|January 19, 2018
Altered B lymphocyte homeostasis and functions in systemic sclerosisAlexandra Forestier, Thomas Guerrier, Mathieu Jouvray, et al.
Multiple Sclerosis and Related Disorders|February 12, 2021
Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS studyBruce A C Cree, James D Bowen, Hans-Peter Hartung, et al.
Digital Health|May 19, 2023
Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosisGavin Giovannoni, Enrique Alvarez, Ellen Tutton, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 13, 2023
Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosisJohn Kramer, Ralf Linker, David Paling, et al.
The New England Journal of Medicine|April 9, 2025
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple SclerosisRobert J Fox, Amit Bar-Or, Anthony Traboulsee, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 14, 2022
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MSNicola de Stefano, Frederik Barkhof, Xavier Montalban, et al.
Lancet (London, England)|March 27, 2018
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 studyLudwig Kappos, Amit Bar-Or, Bruce A C Cree, et al.
BMC Neurology|October 7, 2020
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosisGiancarlo Comi, Mark S Freedman, José E Meca-Lallana, et al.
Frontiers in Immunology|November 3, 2022
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year inMaura Pugliatti, Hans-Peter Hartung, Celia Oreja-Guevara, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 14, 2025
Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?Sandra Vukusic, Florian Hubben, Antoine Gavoille, et al.
Pageof 25